Dermax SA
The score of Dermax shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +74 % Total assets -20 %
Accounts of the company itself (not consolidated).
The full file covers 9 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Dermax's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | €1.55m | ||||
| Net result | 517,589 € | ||||
| Equity | €5.31m | ||||
| Cash | 168,229 € | ||||
| EBITDA | €1.20m | ||||
| Total assets | €5.73m |
Filed annual accounts
- Year ended 31 Dec 2025filed on 07 Jul 2026
- Year ended 31 Dec 2024filed on 04 Jul 2025
- Year ended 31 Dec 2023filed on 15 Nov 2024
- Year ended 31 Dec 2022filed on 11 Jul 2023
- Year ended 31 Dec 2021filed on 12 Jul 2022
Dermax's financial analysis
- Solvency92.8%sector median: 43.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Dermax
Dermax's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0667.730.677
- VAT number
- BE0667730677
- Peppol
- Registered · 0208:0667730677 · as of 04 Nov 2026
- Legal form
- SA
- Incorporated
- 15 Dec 2016
- Registered office
- 4000 Liège
- Latest accounts
- 2025 · filed on 07 Jul 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
Dermax (SA) has been based in Liège since 2016, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports revenue of €1.55m, a net profit of 517,589 € and equity of €5.31m. Its solvency stands at 92.8%, above the median of its sector (43.9%).
Companies similar to Dermax
Companies in the same business, of comparable size and area, outside its group.
- Alexion Pharma Belgium Manufacture of pharmaceutical preparations Brussels · balance sheet €8.74m
- Surveal Pharma Wholesale of pharmaceutical and medical goods Ixelles · balance sheet €5.47m
- Sasmar Pharmaceuticals Wholesale of pharmaceutical and medical goods Overijse · balance sheet €3.07m
- Schwabe Pharma Belgium Wholesale of pharmaceutical and medical goods Kontich · balance sheet €3.13m
- Cirba Wholesale of pharmaceutical and medical goods Ixelles · balance sheet 67,062 €
- Medini Wholesale of pharmaceutical and medical goods Oostkamp · balance sheet €8.77m
- Arkopharma Belux Wholesale of pharmaceutical and medical goods Wavre · balance sheet €5.33m
- Cogezaf Wholesale of pharmaceutical and medical goods Gembloux · balance sheet €6.72m
Frequently asked questions about Dermax
What is the revenue of Dermax?
According to the 2025 annual accounts filed with the NBB, the revenue of Dermax amounts to 1,554,264 €.
What is the VAT number of Dermax?
In Belgium, the VAT number is the company number prefixed with BE: BE0667730677 for Dermax, if the company is VAT-registered. Its company number (CBE) is 0667.730.677.
Where is the registered office of Dermax?
According to the CBE register, the registered office of Dermax is in 4000 Liège.
What is the equity of Dermax?
At the close of the 2025 financial year, the equity of Dermax amounts to 5,312,598 €, a solvency of 92.8% of total assets.
Who manages Dermax?
The register lists 6 active mandates at Dermax. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Dermax
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →